Ignite Creation Date:
2025-12-24 @ 5:40 PM
Ignite Modification Date:
2026-06-10 @ 9:39 AM
Study NCT ID:
NCT02440568
Status:
TERMINATED
Last Update Posted:
2021-07-06
First Post:
2015-05-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Sponsor:
University of Illinois at Chicago
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
2015-0181
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |